Ki-67 is a reliable pathological grading marker for neuroendocrine tumors

Virchows Archiv

Volumn 462, Issue 5, 2013, Pages 501-505

  Nadler, Ashlie ^a   Cukier, Moises ^a   Rowsell, Corwyn ^a   Kamali, Sepideh ^b   Feinberg, Yael ^a   Singh, Simron ^a   Law, Calvin H L ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Carcinoid; Ki 67; Neuroendocrine tumor; Reliability

Indexed keywords

MONOCLONAL ANTIBODY KI 67; KI 67 ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; COMPARATIVE STUDY; FEMALE; HUMAN; INTERRATER RELIABILITY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; REPRODUCIBILITY; WORLD HEALTH ORGANIZATION; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM GRADING; NEUROENDOCRINE TUMORS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

MLCS; MLOWN;

EID: 84879319709     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-013-1410-8     Document Type: Article

References (29)

1. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB (2008) One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063-3072
2. Hauso O, Gustafsson BI, Kidd M, Waldum HL, Drozdov I, Chan AK, Modlin IM (2008) Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer 113:2655-2664
3. Hemminki K, Li X (2001) Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer 92:2204-2210
4. Ellis L, Shale MJ, Coleman MP (2010) Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971. Am J Gastroenterol 105:2563-2569
5. Modlin IM, Moss SF, Chung DC, Jensen RT, Snyderwine E (2008) Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst 100(18):1282-1289
6. Gerdes J, Lemke H, Baisch H, Wacker H-H, Schwab U, Stein H (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133(4):1710-1715
7. Scholzen T, Gerdes J (2000) The Ki-67 Protein: from the known and the unknown. J Cell Physiol 182:311-322
8. Jamali M, Runjan C (2008) Predicting prognosis in gastroentero-pancreatic neuroendocrine tumors: an overview and the value of Ki-67 immunostaining. Endocr Pathol 19:282-288
9. Vilar E, Salazar R, Pérez-García J, Cortes J, Öberg K, Tabernero J (2007) Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer 14:221-232
10. La Rosa S, Sessa F, Capella C, Riva C, Leone BE, Klersy C, Rindi G, Solcia E (1996) Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Arch 429(6):323-333
11. Pape U-F, Berndt U, Müller-Nordhorn J, Böhmig M, Roll S, Koch M, Willich SN, Wiedenmann B (2008) Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 15:1083-1097
12. Pelosi G, Bresaola E, Bogina G, Pasini F, Rodella S, Castelli P, Lacono C, Serio G, Zamboni G (1996) Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Hum Pathol 27(11):1124-1134
13. Arnold R, Rinke A, Klose K-J, Müller H-H, Wied M, Zamzow K, Schmidt C, Schade-Brittinger C, Barth P, Moll R, Koller M, Unterhalt M, Hiddemann W, Schmidt-Lauber M, Pavel M, Arnold CN (2005) Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol 3:761-771
14. Klimstra DS, Modlin IR, Adsay NV, Chetty R, Desphande V, Gönen M, Jensen RT, Kidd M, Kulke MH, Lloyd RV, Moran C, Moss SF, Oberg K, O'Toole D, Rindi G, Robert ME, Suster S, Tang LH, Tzen C-Y, Washington MK, Wiedenmann B, Yao J (2010) Pathology reporting of neuroendocrine tumors: application of the delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol 34(3):300-313
15. Bosman FT, Carneiro F, Hruban RH, Theise ND (2010) WHO classification of tumours of the digestive system. International Agency for Research on Cancer, Lyon
16. Rindi G, Klöppel G, Ahlmann H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, Körner M, Lopes JM, McNicol A-M, Nilsson O, Perren A, Scarpa A, Scoazec J-Y, Wiedenmann B et al (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449:395-401
17. Rindi G, Klöppel G, Couvelard A, Komminoth P, Körner M, Lopes JM, McNicol A-M, Nilsson O, Perren A, Scarpa A, Scoaze J-Y, Wiedenmann B (2007) TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 451:757-762
18. Plöckinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, de Herder WW, Goede A, Caplin M, Öberg K, Reubi JC, Nilsson O, Delle Fave G, Ruszniewski P, Ahlman H, Wiedenmann B (2004) Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumour: a consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 80:394-424
19. Boudreaux JP, Klimstra DS, Hassan MM, Woltering EA, Jensen RT, Goldsmith SJ, Nutting C, Bushnell DL, Caplin ME, Yao JC (2010) The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum. Pancreas 39(6):753-766
20. Lawrence B, Kidd M, Svedja B, Modlin I (2011) A clinical perspective on gastric neuroendocrine neoplasia. Curr Gastroenterol Rep 13:101-109
21. Kocha W, Maroun J, Kennecke H, Law C, Metrako P, Ouellet JF, Reid R, Rowsell C, Shah A, Singh S, Uum SV, Wong R (2010) Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian National Expert Group. Curr Oncol 17(3):49-64
22. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S (2010) The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading and staging systems. Pancreas 39(6):707-712
23. Mengel M, von Wasielewski R, Wiese B, Rüdiger T, Müller-Hermelink HK, Kreipe H (2002) Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial. J Pathol 198:292-299
24. Elie N, Plancoulaine B, Signolle J-P, Herlin P (2003) A simple way of quantifying immunostained cell nuclei on the whole histologic section. Cytometry A 56(1):37-45
25. Lejeune M, Jaén J, Pons L, López C, Salvadó M-T, Bosch R, Garcia M, Escrivà P, Baucells J, Cugat X, Álvaro T (2008) Quantification of diverse subcellular immunohistochemical markers with clinicobiological relevancies: validation of a new computer-assisted image analysis procedure. J Anat 212:868-878
26. Dhall D, Frishberg DP, Galliano G, Chiles L, Chung F, Ines D, Wang HL (2009) Interobserver variability in assessing Ki-67 proliferative index in gastrointestinal well-differentiated neuroendocrine neoplasms. Mod Pathol 22:116A
27. Goodell PP, Krasinskas AM, Davison JM, Hartman DJ (2012) Comparison of methods for proliferative index analysis for grading pancreatic well-differentiated neuroendocrine tumors. Am J Clin Pathol 137:576-582
28. Lowe K, Khithani A, Liu E, Winston T, Christian D, Saad J, Jeyarajah DR (2012) Ki-67 labeling: a more sensitive indicator of malignant phenotype than mitotic count or tumor size? J Surg Oncol 106(6):724-727
29. Pavel M, Baudin E, Couvelard A, Krenning E, Oberg K, Steinmuller T, Anlauf M, Wiedenmann B, Salazar R et al (2012) ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95:157-176